Emergent BioSolutions gets $24M BARDA contract modification for CYFENDUS anthrax vaccine

Emergent BioSolutions Inc.

Contract modification valued at ~$24M from BARDA to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness.
Modification No. 21 to BARDA AV7909 Contract, effective Aug 18, 2026; announced Sept 1, 2026.
Earlier in 2026, Emergent announced up to $21.5M delivery order for BioThrax to U.S. Department of War.
CYFENDUS approved by FDA in July 2023 as two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.